Nitric Oxide Synthase, Green Tea Catechins and Parkinson’s Disease

Tea in Health and Disease Prevention

Volumn , Issue , 2013, Pages 1425-1431

  Kim, Ji Seon ^a   Oh, Eung Seok ^b   Kim, Jong Min ^b  

^a Chungbuk National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882833938     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384937-3.00119-1     Document Type: Chapter

References (40)

1. A. Ascherio, S.M. Zhang, Hernan, et al. (2001) Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann. Neurol. 50 56-63.
2. D.A. Balentine, S.A. Wiseman and L.C. Bouwens (1997) The chemistry of tea flavonoids. Crit. Rev. Food Sci. Nutr. 37 693-704.
3. J.L. Barranco Quintana, M.F. Allam, A.S. Del Castillo and R.F. Navajas (2009) Parkinson's disease and tea: a quantitative review. J. Am. Coll. Nutr. 28(1), 1-6.
4. R.K. Chaturvedi, S. Shukla, K. Seth, et al. (2006) Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neurobiol. Dis. 22(2), 421-434.
5. S.J. Chinta and J.K. Andersen (2008) Redox imbalance in Parkinson’s disease. Biochim. Biophys. Acta 1780 1362-1367.
6. J.Y. Choi, C.S. Park, D.J. Kim, et al. (2002) Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology 23 367-374.
7. L.M. de Lau and M.M. Breteler (2006) Epidemiology of Parkinson's disease. Lancet Neurol. 5(6), 525-535.
8. J. Eriksen, T. Dawson, D. Dickson and L. Petrucelli (2003) Caught in the act: α-synuclein is the culprit in Parkinson’s disease. Neuron 40 453-456.
9. T. Gasser (2001) Genetics of Parkinson’s disease. J. Neurol. 248 833-840.
10. J.T. Greenamyre and T.G. Hastings (2004) Parkinson's–divergent causes, convergent mechanisms. Science 304(5674), 1120-1122.
11. L.N. Grinberg, H. Newmark, N. Kitrossky, et al. (1997) Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem. Pharmacol. 54 973-978.
12. T.M. Haqqi, D.D. Anthony, S. Gupta, et al. (1999) Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc. Natl. Acad. Sci. USA 96 4524-4529.
13. J. Hardy (2010) Genetic analysis of pathways to Parkinson disease. Neuron 68(2), 201-206.
14. C.H. Hawkes, K. Del Tredici and H. Braak (2010) A timeline for Parkinson's disease. Parkinsonism Relat. Disord. 16(2), 79-84.
15. M.A. Hernan, B. Takkouche, F. Caamaño-Isorna and J.J. Gestal-Otero (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52(3), 276-284.
16. G. Hu, S. Bidel, P. Jousilahti, et al. (2007) Coffee and tea consumption and the risk of Parkinson's disease. Mov. Disord. 22(15), 2242-2248.
17. B. Kandinov, N. Giladi and A.D. Korczyn (2007) The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease. Parkinsonism Relat. Disord. 13(4), 243-245.
18. B. Kandinov, N. Giladi and A.D. Korczyn (2009) Smoking and tea consumption delay onset of Parkinson's disease. Parkinsonism Relat. Disord. 15(1), 41-46.
19. D. Kaur and J. Andersen (2004) Does cellular iron dysregulation play a causative role in Parkinson's disease? Ageing Res. Rev. 3(3), 327-343.
20. J.S. Kim, J.M. Kim, J.J. O and B.S. Jeon (2010) Inhibition of inducible nitric oxide synthase expression and cell death by (−)-epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Clin. Neurosci. 17(9), 1165-1168.
21. M. Kimura, K. Umegaki, Y. Kasuya, et al. (2002) The relation between single/double or repeated tea catechin ingestions and plasma anti-oxidant activity in humans. Eur. J. Clin. Nutr. 56 1186-1193.
22. M. Kumamoto, T. Sonda, K. Nagayama and M. Tabata (2001) Effects of pH and metal ions on anti-oxidative activities of catechins. Biosci. Biotechnol. Biochem. 65 126-132.
23. Y. Levites, O. Weinreb, G. Maor, et al. (2001) Green tea polyphenol (−)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78(5), 1073-1082.
24. Y. Levites, M.B. Youdim, G. Maor and S. Mandel (2002) Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol. 63 21-29.
25. G.T. Liberatore, V. Jackson-Lewis, S. Vukosavic, et al. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5(12), 1403-1409.
26. S. Mandel, G. Maor and M.B. Youdim (2004) Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (−)-epigallocatechin-3-gallate. J. Mol. Neurosci. 24(3), 401-416.
27. S. Mandel, O. Weinreb, T. Amit and M.B. Youdim (2004) Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (−)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J. Neurochem. 88 1555-1569.
28. S.A. Mandel, Y. Avramovich-Tirosh, L. Reznichenko, et al. (2005) Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals 14 46-60.
29. J.F. Morley and H.I. Hurtig (2010) Current understanding and management of Parkinson disease: five new things. Neurology 75(Suppl. 1–18), S9-S15.
30. B. Ravina, S.C. Fagan, R.G. Hart, et al. (2003) Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60(8), 1234-1240.
31. R. Saunders-Pullman (2003) Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both? Endocrine 21 81-87.
32. A.H. Schapira and C.W. Olanow (2004) Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291(3), 358-364.
33. I. Shoulson (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328(3), 176-183.
34. C.W. Shults, D. Oakes, K. Kieburtz, et al., Parkinson Study Group (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59(10), 1541-1550.
35. B.A. Sutherland, R.M. Rahman and I. Appleton (2006) Mechanisms of action of green tea catechins, with a focus on ischemia-induced neurodegeneration. J. Nutr. Biochem. 17 291-306.
36. L.C. Tan, W.P. Koh, J.M. Yuan, et al. (2008) Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. Am. J. Epidemiol. 167(5), 553-560.
37. E.K. Tan, C. Tan, S.M. Fook-Chong, et al. (2003) Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J. Neurol. Sci. 216(1), 163-167.
38. Z.Y. Wang, M.T. Huang, Lou, et al. (1994) Inhibitory effects of black tea, green tea, decaffeinated black tea, and decaffeinated green tea on ultraviolet B light-induced skin carcinogenesis in 7,12-dimethylbenz[a]anthracene-initiated SKH-1 mice. Cancer Res. 54 3428-3435.
39. K.F. Winklhofer and C. Haass (2010) Mitochondrial dysfunction in Parkinson’s disease. Biochim. Biophys. Acta 1802 29-44.
40. A.H. Wu, K. Arakawa, F.Z. Stanczyk, et al. (2005) Tea and circulating estrogen levels in postmenopausal Chinese women in Singapore. Carcinogenesis 26 976-980.